The Sample Taken Before Sydney, and the Second Page of Marathon's Biggest Story

I have an old habit — before every big race, I build a sheet with the travel grant, the entry list and the qualifying window. In 2026, when I built my first live ledger for FC Pune City in Pune, I thought metrics would explain everything. Seven years later, looking at the result of the 30 August 2026 Sydney Marathon, I was opening that same sheet — two hours, 18 minutes, 31 seconds, and more than three minutes ahead of compatriot Irene Chepet Cheptai in second. On paper, it was a one-sided race. The paper did not say that before this, in Kenya, an out-of-competition sample taken before the race had come back positive.

The Athletics Integrity Unit (AIU) has provisionally suspended Peres Jepchirchir. The sample tested positive for EPO (erythropoietin). This is the same 33-year-old athlete who won the women's marathon gold at the 2026 Tokyo Olympics and then completed a rare double by winning the World Championships in the same city in September 2026. In 2026 she broke the women's half-marathon world record, and in 2026 she improved it three more times. New York 2026, Boston 2026, London 2026 — this is the list of an athlete who has put her name on nearly every major road in marathoning over the past five years.

EPO is no foreign word. It is a hormone produced naturally in the kidneys that stimulates the creation of new red blood cells. Injected, it is detectable in urine or blood only for a short window, and it increases the amount of red blood cells — the vehicles that carry oxygen to the muscles. In an event like the marathon, the implication is clear: in the final 10 kilometres, where the body fights oxygen debt, an invisible backup is ready.

Here I will write what I usually say loudly at the data desk — the EPO case is a case about timing, and timing is the weakest part of this whole story. Jepchirchir provided the sample in Kenya, before the Sydney race. Which means the victory recorded on 30 August was built on a road that now sits under scrutiny. Under AIU procedure, a provisional suspension means the athlete cannot compete until the case is resolved. This is not a punishment — it is a hold. But in sports journalism we often erase that distinction, and that is where the story turns in the wrong direction.

I have been in this profession since 2026. When I sat at The Indian Express sports desk in Kolkata, doping stories came over the teleprinter in a single paragraph and became a two-column report the next day. Nobody asked about the chain of custody of the sample then. Now we have bodies like the AIU, the biological passport, and the athlete passport data that tells the story of an athlete's blood over years. But what reaches the reader is still that same single paragraph — name, substance, suspension. And the most important question is left out: what ground was this victory standing on?

Let us measure that ground. The Sydney Marathon became the seventh World Major in 2026 — an expansion that changed the economic architecture of marathoning. World Major status means a bigger prize purse, a bigger broadcast, and a bigger field of international elites. On 30 August 2026, Jepchirchir's 2:18:31 was significant as a strong performance on that course — a margin of over three minutes is rare in any major. But my sheet has another column: the training block before the race. Altitude training in Kenya, then travel to Sydney, then the race. This is the same routine generations of Kenyan marathoners have followed. And that same routine creates the most sensitive window for EPO — because at altitude the body's natural red blood cell production rises, and hiding the presence of external EPO becomes complicated. Let me be clear here: this is not a defence, it is a technical note I enter in my ledger.

Look at the number of Kenyan athletics doping cases in recent years and a pattern appears. Since 2026 Kenya was placed in WADA's 'high risk' category, and since then the number of sample collections has risen sharply. That also means the detection rate has risen — and that is good news, even if the headlines look bad. When you increase out-of-competition testing, positives rise too. The question is not whether there is more cheating in Kenya; the question is how deep the testing net reaches. I have a lesson from the 2026 Russia World Cup desk — when you build data cards for a tournament, the first thing you write is how big the sample is. The same rule should apply to doping coverage: before the number of positive cases, look at the number of tests.

Now the part that troubles me most. If we see Jepchirchir's story only through the doping lens, we forget the athlete who won Olympic gold in Tokyo and then won the World Championships in the same city. That is rare — winning both Olympic and World Championship marathons. But if we only count her achievements, we forget the system that made them possible. And here is my contrarian angle: the biggest failure in this case is not that an EPO test came back positive — the failure is that we had no independent verification before that race. The 2:18:31 in Sydney came, but nobody asked what the athlete's biological profile looked like in the weeks behind that time. The AIU has the athlete biological passport, but that data does not reach the public. The result: we celebrate results and wait for samples.

This is an old complaint of mine. In 2026 in Pune, when I was building the set-piece xG ledger, I thought data would make everything transparent. But data only works when it is logged on time. I myself missed the post-match logging deadline twice, and after that I built a 24-hour follow-up checklist. In the same way, doping coverage must bridge the gap between 'when the sample was taken' and 'when the result came'. Jepchirchir's sample was taken before the race, the result came after. In between she won the race, took the prize money, and her victory story was printed in the media. This is the natural speed of process, but within that speed it is necessary to tell the reader that the story is not finished yet.

One more thing I write on my sheet: the economics of marathoning is now not just about the race, but about the media cycle. Sydney becoming a World Major, competing with brands like New York-Boston-London, and rising prize purses for elite athletes — all of this builds an ecosystem where a positive test is not just one athlete's story, but the story of the event's brand. For the Sydney Marathon organisers this is difficult — they earned Major status in 2026, and in 2026 a shadow of suspension fell on their winner. But this is exactly where sports administration must be strict: if an event wants to be a World Major, it must pay the same price for the integrity of its elite field that it pays for branding.

I am not pronouncing a verdict in this case. The AIU process will run, there is a right to the B sample, a right to appeal. But I can say this: after this news, the story of marathoning that gets written will not only be about 2:18:31. It will be about the question of how we measured that time, and whether we even tried to measure it.

Last year, when she won the World Championships in Tokyo, I wrote a note — 'winning the World Championships after the Olympics happens once in a generation in marathoning.' That note is still in my diary. I will not erase it. But under it I will add a new line: 'and remember also that behind every record there is a sample, and behind every sample a process.' That will be the first sentence of my next report.

Next time a marathon winner is announced, do not just look at the time. Look at the entry list, look at the testing pool, and ask who logged the data of that victory. Because in a sport where we call results history, the sample must also be part of history — even if it arrives late.